The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes

• Published in: Diabetes therapy Vol. 11; no. 4; pp. 835 - 844
• Main Authors: Yin, Win L., Bain, Steve C., Min, Thinzar
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.04.2020; Springer; Springer Nature B.V
• Subjects: Cardiology; Cardiovascular diseases; Care and treatment; Chronic kidney failure; Complications and side effects; Diabetes; Diabetic nephropathy; Drug therapy; Endocrinology; Glucagon; Hypoglycemic agents; Inhibitor drugs; Internal Medicine; Kidney diseases; Medicine; Medicine & Public Health; Patient outcomes; Peptides; Prevention; Review; Risk factors; Type 2 diabetes; United Kingdom; Type 2 diabetes; Diabetic nephropathy; Chronic kidney disease; Dipeptidyl peptidase-4 (DPP-4) inhibitors; Glucagon-like peptide-1 receptor agonists; Diabetes-related nephropathy
• ISSN: 1869-6953; 1869-6961
• DOI: 10.1007/s13300-020-00798-x

This review examines the available literature on the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on renal outcomes in type 2 diabetes mellitus. Diabetes is an important cause of end-stage renal disease requiring renal replacement therapy, and diabetic kidney disease is an independent risk factor for cardiovascular disease (CVD). GLP-1RAs are proven to be safe in terms of CVD, and some of them have been shown to have a beneficial effect on cardiovascular outcomes. The effect of GLP-1RAs on hard renal endpoints has yet to be established; to date, there have been no published GLP-1RA clinical trials with primary renal endpoints. In this review, we discuss the evidence for a renal protective role of GLP-1RAs, highlighting the secondary renal outcomes from recent cardiovascular outcome trials of this class of glucose-lowering therapies.